Patents by Inventor Vincent Zoete
Vincent Zoete has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240180965Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.Type: ApplicationFiled: July 6, 2023Publication date: June 6, 2024Inventors: Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao
-
Patent number: 11945879Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.Type: GrantFiled: August 18, 2020Date of Patent: April 2, 2024Assignees: Jean Kadouche, Centre National de la Recherche Scientifique, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, University of LausanneInventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
-
Publication number: 20230414660Abstract: The present disclosure relates to novel PD-1 decoy variants, compositions, and methods to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified subsets of lymphocytes.Type: ApplicationFiled: November 12, 2021Publication date: December 28, 2023Applicants: Ludwig Institute for Cancer Research Ltd, Centre Hospitalier Universitaire Vaudois, University of LausanneInventors: George Coukos, Melita Irving, Vincent Zoete
-
Patent number: 11738049Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.Type: GrantFiled: May 24, 2018Date of Patent: August 29, 2023Assignees: SIB Swiss Institute of Bioinformatics, CHUV—Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Ludwig Institute for Cancer Research LtdInventors: Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao
-
Publication number: 20220387555Abstract: The present disclosure relates to methods and compositions to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified subsets of lymphocytes. The disclosure provides compositions comprising genetically-modified lymphocytes that express at least two transgene(s) having the ability to modulate the immune system and the innate and adaptive immune response.Type: ApplicationFiled: November 13, 2020Publication date: December 8, 2022Applicant: Ludwig Institute for Cancer Research LtdInventors: George Coukos, Melita Irving, Angel de Jesus Corria Osorio, Vincent Zoete
-
Publication number: 20220185793Abstract: The pesent invention relates to compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof and their use for the prevention and treatment of oncovirus induced cancer in a subject.Type: ApplicationFiled: April 9, 2020Publication date: June 16, 2022Inventors: Rajwinder Lehal, Guido Bold, Charlotte Urech, Vincent Zoete
-
Publication number: 20220169642Abstract: The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.Type: ApplicationFiled: April 9, 2020Publication date: June 2, 2022Inventors: Rajwinder Lehal, Guido Bold, Charlotte Urech, Vincent Zoete
-
Publication number: 20220152109Abstract: The application provides genetically modified cell receptors (TCRs) specific for an epitope from cancer antigen NY-ESO-1. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells, including but not limited to genetically engineered cells, and pharmaceutical compositions. The application further provides the use of such modified T cell receptors (TCRs) and related compositions for cancer immunotherapy (e.g., adoptive cell therapy).Type: ApplicationFiled: March 17, 2020Publication date: May 19, 2022Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: George COUKOS, Melita IRVING, Vincent ZOETE, Olivier MICHIELIN
-
Publication number: 20210040235Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CHI and CL domains, said mutations preventing heavy chain/light chain mispairing.Type: ApplicationFiled: August 18, 2020Publication date: February 11, 2021Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
-
Publication number: 20200385490Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CHI and CL domains, said mutations preventing heavy chain/light chain mispairing.Type: ApplicationFiled: August 18, 2020Publication date: December 10, 2020Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
-
Patent number: 10815310Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.Type: GrantFiled: March 20, 2017Date of Patent: October 27, 2020Assignees: Centre National de la Recherche Scientifique, Azienda socio sanitaria territoriale Papa Giovanni XXIII, Universite de LausanneInventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
-
Publication number: 20200101110Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.Type: ApplicationFiled: May 24, 2018Publication date: April 2, 2020Inventors: Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao
-
Patent number: 10174078Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, keratan sulfate. The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of keratan-sulfate expressing cells in vitro and in vivo.Type: GrantFiled: April 27, 2015Date of Patent: January 8, 2019Assignee: PHI PHARMA SAInventors: Christophe Bonny, Fabrice Chenaux, Vincent Zoete
-
Patent number: 10131690Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, chondroitin 6-sulfate (C6S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C6S expressing cells in vitro and in vivo.Type: GrantFiled: April 27, 2015Date of Patent: November 20, 2018Assignee: PHI PHARMA SAInventors: Christophe Bonny, Fabrice Chenaux, Vincent Zoete
-
Publication number: 20180022829Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.Type: ApplicationFiled: March 20, 2017Publication date: January 25, 2018Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
-
Publication number: 20170137465Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, chondroitin 6-sulfate (C6S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C6S expressing cells in vitro and in vivo.Type: ApplicationFiled: April 27, 2015Publication date: May 18, 2017Inventors: Christophe BONNY, Fabrice CHENAUX, Vincent ZOETE
-
Publication number: 20170114094Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, keratan sulfate. The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of keratan-sulfate expressing cells in vitro and in vivo.Type: ApplicationFiled: April 27, 2015Publication date: April 27, 2017Inventors: Christophe BONNY, Fabrice CHENAUX, Vincent ZOETE
-
Patent number: 9631031Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.Type: GrantFiled: July 6, 2012Date of Patent: April 25, 2017Assignees: Centre National de la Recherche Scientifique, Azienda Ospedaliera Papa Giovanni XXIII, Universite de LausanneInventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
-
Publication number: 20140242076Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.Type: ApplicationFiled: July 6, 2012Publication date: August 28, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE LAUSANNE, AZIENDA OSPEDALIERA PARA GIOVANNI XXIIIInventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay